


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+9.60%
-9.82%
-1.00%
-0.49%
+1.01%
MBRX
Moleculin Biotech Inc.
$4.98
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
MBRX Price Performance
$0.42 (+1085.71%)
$0.4 (+1145.00%)
$0.64 (+678.13%)
$1.81 (+175.14%)
MBRX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

Low volume

High volatilty

MBRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MBRX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is MBRX current stock price?
What are MBRX stock strengths?
What is MBRX Risk Level?
What is MBRX market cap and volume?
What is MBRX current Stock IQ?
Should I buy MBRX stock right now?
Is MBRX a Strong Buy right now?
What does a 'Strong Buy' rating mean for MBRX?
What does a 'Strong Sell' rating mean for MBRX?
What factors influence MBRX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.60%
-9.82%
-1.00%
-0.49%
+1.01%
MBRX
Moleculin Biotech Inc.
Current Price
$4.98
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

MBRX Price Performance
$0.42 (+1085.71%)
$0.4 (+1145.00%)
$0.64 (+678.13%)
$1.81 (+175.14%)
MBRX Analysts Opinion
MBRX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MBRX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook
MBRX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

Low volume

High volatilty

Average key support and resistance price levels
MBRX Stock IQ
MBRX Latest Analysis
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation. Fintel reports that on December 11 2025 HC Wainwright &. Co. maintained coverage of Moleculin Biotech (NasdaqCM:MBRX) with a Buy recommendation. Analyst Price Forecast Suggests 3419.67% Upside
Thu Dec 11, 2025
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds. HOUSTON Dec. 10 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech Inc. (Nasdaq: MBRX) (Moleculin or the Company) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727969 shares
Wed Dec 10, 2025
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain | DelveInsight. Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain |. DelveInsightAcute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults the global rise in aging populations i
Thu Dec 4, 2025
Moleculin Biotech To Present Corporate Overview At Virtual Investor Closing Bell Series . (RTTNews) - Moleculin Biotech Inc. (MBRX) announced that it will participate in the Virtual Investor Closing Bell Series on Tuesday December 2 2025 at 4:00 PM ET. Chairman and Chief Executive Officer Walter Klemp will provide a corporate overview and business outlook followed
Fri Nov 28, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MBRX Stock trends
MBRX Stock performance
MBRX Stock analysis
MBRX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.